早期乳腺癌輔助化療進(jìn)展中國(guó)醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院徐兵河(已修改)
2025-06-07 12:07 本頁(yè)面
【正文】 早期乳腺癌輔助化療進(jìn)展 中國(guó)醫(yī)學(xué)科學(xué)院腫瘤醫(yī)院 徐兵河 Breast Cancer Incidence Trends Over Time Cancer Incidence Trends in China 2022 – 2022 Incidence Rates Projection by Cancer Type 01020304050602022 2022 2022 2022G a s t r i cC o l o n / R e c t u mL i v e rLungB r e a s tP r o s t a t ePer 100,000 CAGR % CAGR % CAGR % CAGR –% CAGR % CAGR % Source: Estimates of Cancer Incidence in China for 2022 and Projections for 2022, Yang L, et al. 中國(guó)乳腺癌發(fā)病概況 ?每年約有 19萬(wàn)新發(fā)乳腺癌病例 2022年全國(guó)乳腺癌年齡標(biāo)化 發(fā)病率:,000； 死亡率 : ,000 ?發(fā)病率：城市 ＞農(nóng)村 ?高發(fā)年齡段： 45－ 50歲 近 15年來(lái)乳腺癌 發(fā)病率上升 死亡率下降 死亡率下降的原因 ?早期診斷 ?綜合治療 The benefits of chemotherapy data from clinical trails ? Early Breast Cancer Trialists39。 Collaborative Group (EBCTCG). ? 194 randomised trials of adjuvant chemotherapy (CMF,CAF,CEF) or hormonal therapy (TAM) that began by 1995. Lancet 2022 Placebo % 0 10 20 30 40 50 60 Time (years) 0 5 15 10 Recurrence (%) 15year gain % (SE ) Logrank 2p 15year probabilities of recurrence in women aged 50 years, with / without polychemotherapy Polychemotherapy % Younger women, 35% nodepositive。 older women, 70% nodepositive。 SE=standard error EBCTCG. Lancet 2022。 365: 16871717 Placebo % 0 10 20 30 40 50 60 Breast cancer mortality (%) 15year gain % (SE ) Logrank 2p Polychemotherapy % Time (years) 0 5 15 10 15year probabilities of breast cancer mortality in women aged 50 years, with / without polychemotherapy EBCTCG. Lancet 2022。 365: 16871717 Younger women, 35% nodepositive。 older women, 70% nodepositive 0 10 20 30 40 50 60 15year gain % (SE ) Logrank 2p Placebo % Polychemotherapy % 0 5 15 10 15year probabilities of recurrence in women aged 5069 years, with / without polychemotherapy Time (years) EBCTCG. Lancet 2022。 365: 16871717 Recurrence (%) Younger women, 35% nodepositive。 older women, 70% nodepositive Placebo % 0 10 20 30 40 50 60 15year gain % (SE ) Logrank 2p Polychemotherapy % 0 5 15 10 15year probabilities of breast cancer mortality in women aged 5069 years, with / without polychemotherapy Time (years) Younger women, 35% nodepositive。 older women, 70% nodepositive EBCTCG. Lancet 2022。 365: 16871717 Breast cancer mortality (%) Placebo % 0 10 20 30 40 50 60 15year gain % (SE ) Logrank 2p 15year probabilities of recurrence in women with ER+ (or ERunknown) disease, with / without ~5 years39。 tamoxifen About 5 years39。 tamoxifen % Time (years) 0 5 15 10 ER=oestrogen receptor。 10,386 women: 20% ERunknown, 30% nodepositive EBCTCG. Lancet 2022。 365: 16871717 Recurrence (%) 0 10 20 30 40 50 60 15year gain % (SE ) Logrank 2p Placebo % About 5 years39。 tamoxifen % 0 5 15 10 15year probabilities of breast cancer mortality in women with ER+ (or ERunknown) disease, with / without ~5 years39。 tamoxifen Time (years) 10,386
環(huán)評(píng)公示相關(guān)推薦
鄂ICP備17016276號(hào)-1